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Zusammenfassung
Hintergrund: Die Behandlung des metastasierten cholan-
giozellulären Karzinoms ist nach wie vor unbefriedigend,
da dieser Tumor im allgemeinen als chemotherapieresi-
stent eingestuft wird. In den fortgeschrittenen Stadien
richten sich die therapeutischen Bemühungen daher auf
die Palliation. Patienten und Methoden: Wir berichten
über 2 Patienten mit hepatisch metastasiertem cholan-
giozellulärem Karzinom. Beide hatten bereits eine Che-
motherapie im metastasierten Stadium erhalten [lokale,
intraarterielle Chemotherapie mit 5-Fluorouracil (5-FU) /
Folinsäure (FA) und Oxaliplatin bzw. systemisch 5-FU/FA
und Gemcitabin]. Nachdem die Erkrankung im Verlauf
progredient war, wurde eine orale Therapie mit Capecita-
bin eingeleitet (2500 mg/m2 täglich, verteilt auf 2 Dosen
über 14 Tage). Ergebnisse: Capecitabin wurde ohne
schwerwiegende Nebenwirkungen von beiden Patienten
gut toleriert. Wie in den bildgebenden Verfahren als auch
anhand der Tumormarkerverläufe dokumentiert, konnte
durch die Therapie eine weitere Progression des Tumor-
leidens verhindert und eine klinische Stabilisierung er-
reicht werden. Schlussfolgerung: Capecitabin kann zur
Second-Line-Therapie bei Patienten mit progredientem,
metastasiertem cholangiozellulärem Karzinom erwogen
werden.
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Summary
Background: The management of recurrent, metastatic
cholangiocarcinoma still remains a problem since this
tumor entity is classified as chemotherapy-resistant.
When advanced or metastatic disease is diagnosed, the
therapeutic efforts are essentially directed toward pallia-
tion. Patients and Methods: We report on 2 patients suf-
fering from metastatic cholangiocarcinoma. Both had re-
ceived previous chemotherapy for metastatic disease, in-
cluding hepatic artery infusion [5-fluorouracil (5-FU) /
folinic acid (FA) and oxaliplatin] and a combination thera-
py consisting of 5-FU/FA and gemcitabine. Since a pro-
gression of the disease was diagnosed, both patients
were started on oral capecitabine at a daily dose of 
2,500 mg/m2 in 2 divided doses for 2 weeks, followed by
1 week rest. Results: Capecitabine was tolerated well
and severe side effects were not observed. A stop of pro-
gression, documented by imaging procedures and tumor
marker kinetics, was achieved in both patients. Conclu-
sion: Capecitabine could potentially be used for second-
line treatment in patients with progressive metastatic
cholangiocarcinoma.
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Introduction
With an incidence of 2–3/100,000/year in Europe, cholangio-
carcinoma is one of the minor frequent cancer entities. Unre-
sectable and metastatic cholangiocarcinoma has a dismal
prognosis, and the 5-year survival rate is generally less than
5% [1]. In the early stage of the disease, when a curative re-
section is possible, there are few or no symptoms. Symptoms
occur at a late stage, so most patients are unresectable at diag-
nosis [1].
Therapeutic efforts at the metastatic stage are essentially di-
rected toward palliation. Neither single drugs nor the mostly
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5-fluorouracil(5-FU)-based combination regimens, with re-
sponse rates of 25–30%, achieved a clinically meaningful pro-
longation of survival [1].
Capecitabine is a new, orally administrable fluoropyrimidine
carbamate. After oral application the drug passes intactly
through the intestinal mucosa and is first metabolized in the
liver. The further catalytic activation to 5-FU occurs at the
tumor site by the tumor-associated thymidine phosphorylase,
thereby minimizing the exposure of healthy body tissues to
systemic 5-FU [2–5]. The activity of the thymidine phosphory-
lase in liver metastases is statistically higher as in normal tis-
sue [2–5]. Human pharmacokinetic studies have shown that
the drug is well absorbed and rapidly converted to nontoxic
intermediates [2–5]. As shown in preclinical and clinical stud-
ies, capecitabine was highly active against several solid tumors,
and in both 5-FU-sensitive and 5-FU-resistant tumors [2–6]. In
a pilot study of oral capecitabine for hepatobiliary cancers, the
remission rate amounts to 16% [6].
The intermittent regimen is generally recommended, meaning
the daily administration of 2,500 mg/m2 divided in 2 doses for
2 weeks, followed by 1 week without treatment [7, 8].
Case Reports
Methods
Patients were treated with capecitabine at a daily dose of 2,500 mg/m2
given orally divided in 2 doses over a period of 14 days, followed by one
week rest. No premedication was given routinely. Tumor marker kinetics
(CA19–9) were measured before the beginning of every new treatment
cycle, and imaging procedures (ultrasound) were performed after every 2
cycles. 
Case 1
A 47-year-old female was diagnosed with locally advanced cholangiocar-
cinoma in December 1999 (T3 N2 M0 G2–3). The patient was started on a
neoadjuvant, locoregional therapy (hepatic artery infusion, HAI) consist-
ing of mitoxantrone, 5-FU / folinic acid (FA) and cisplatin (12/1999 –
1/2000). After 2 cycles the tumor was surgically removed (histopathologi-
cal staging: pT3 pN2(6/16) G2–3 R1). In February 2000, liver metastases
were diagnosed. Due to limitation of the disease to the liver, locoregional
therapy was continued (5-FU/FA/oxaliplatin). After 4 cycles, a partial re-
mission was achieved and CA19-9 levels had decreased significantly
(CA19-9 2/2000: 29,000 U/ml; 7/2000: 796 U/ml). HAI was continued by
omitting oxaliplatin due to grade 3 neuropathy. After 4 additional cycles,
CA19-9 levels had decreased continuously to a minimum value of 42 U/ml
(December 2000). Since rising CA19-9 levels and a progression of the he-
patic metastasis were diagnosed in February 2001, the patient was started
on oral capecitabine, which was tolerated well (3,500 mg orally per day,
given in 2 divided doses).
Until now, the patient has received 6 cycles of capecitabine, which were
tolerated well. Imaging procedures and CA19-9 values documented a stop
of progression and a stabilization of the disease. 
Case 2
A 71-year-old male was diagnosed with metastatic cholangiocarcinoma in
December 2000. Systemic combination chemotherapy, consisting of gemc-
itabine and 5-FU/FA, was begun. As documented by CT scan after 
3 treatment cycles, a clinical stabilization of the disease was achieved.
Therapy was continued until May 2001 when progression of liver metasta-
sis was diagnosed. The patient was started on capecitabine (4,500 mg oral-
ly per day, given in 2 divided doses) which was tolerated without severe
side effects.
Until now, the patient has received 4 cycles of capecitabine. Except for
mild hand-foot syndrome after the 3rd cycle, capecitabine was tolerated
well. Imaging procedures and CA19-9 values demonstrated a clinical sta-
bilization of the disease. 
Discussion
With an incidence of 2–3/100,000/year in Europe, cholangio-
carcinoma is one of the minor frequent cancer entities [1]. The
higher stages as unresectable or metastatic cholangiocarcino-
ma have a dismal prognosis, with a 5-year survival rate of, gen-
erally, less than 5% [1]. Therapeutic efforts at the advanced or
metastatic stages are therefore essentially directed toward pal-
liation. Neither single drugs nor the mostly 5-FU-based com-
bination regimens achieved a clinically meaningful prolonga-
tion of survival, so current chemotherapeutic options are un-
satisfactory [1]. 
New approaches to improve the response to chemotherapy
have been the introduction of new drugs (gemcitabine/oxali-
platin/irinotecan) or locoregional treatment (hepatic artery in-
fusion, HAI) which was associated with the highest response
rates [9, 10]. Both approaches have not been evaluated exten-
sively so far, and a prolongation in survival has not been
shown yet.
Capecitabine (N4-pentoxycarbonyl-5’-deoxy-5-fluorocytidine,
Xeloda; Hoffman-La Roche AG, Grenzach-Wyhlen, Ger-
many) is a novel, orally administrable fluoropyrimidine car-
bamate which is selectively tumor-activated to 5-FU by ex-
ploiting the higher levels of thymidine phosphorylase found
in tumor tissues compared with normal tissues [2–5]. The drug
provides patients with an opportunity to undergo oral, outpa-
tient fluoropyrimidine therapy.
Phase I trials have examined capecitabine either alone in con-
tinuous and intermittent regimens or combined with FA in an
intermittent regimen. Phase II trials, in patients with metastat-
ic colorectal cancer (CRC), have shown that none of the three
mentioned regimens was markedly superior in terms of induc-
tion of durable objective responses. The intermittent regimen
(2,500 mg/m2/day, orally twice daily, days 1–14 and 7 days rest)
is thereby similar in concept and design to the continuous in-
fusion regimens of 5-FU tested and was found to be promising
in studies conducted by the NCIC and Southwest Oncology
Group [8]. 
The toxicity profile and the most frequent adverse events
(grade 3 and 4, NCI-CTC) involved the gastrointestinal tract
(diarrhea ca. 13%, nausea and vomiting) and the integument
(hand-foot syndrome ca. 9%). Consistent with the dose-limit-
ing toxicity of 5-FU as continuous infusion, capecitabine is
dose-limited by diarrhea and the hand-foot syndrome [11–15].
In a randomized phase III trial in patients with metastatic
CRC, the overall response rate amounted to 25.7%, which
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was statistically significantly superior to 5-FU/FA therapy (p < 0.0002) [12, 14]. Even
in 5-FU-adjuvant pretreated patients there was a significantly better response to
capecitabine as compared to 5-FU (21 vs 9%), while time to progression and sur-
vival were comparable in both groups. In the group of patients treated with
capecitabine, there was a statistically significant lower incidence of grade 3 and 4
toxicities compared with the 5-FU-treated group [12, 14]. In a pilot study of oral
capecitabine for hepatobiliary cancers, the overall remission rate amounted to 16%
and the most common toxicity was the hand-and-foot syndrome (37%). The study
has shown that capecitabine can be safely given to patients with hepatobiliary can-
cers, even to patients with liver cirrhosis [6].
In our reported patients, both of whom had been pretreated, we did not observe any
grade 3 or grade 4 toxicity. All administered cycles were tolerated well, except for
mild hand-foot syndrome after the 3rd cycle in 1 patient. Despite pretreatment with
a 5-FU-based regimen, stabilization of the disease was achieved in both patients. 
In conclusion, capecitabine could potentially be used for the treatment of metastat-
ic cholangiocarcinoma. Further studies are necessary to evaluate the role of
capecitabine as a single agent or in combination in the management of recurrent,
metastatic cholangiocarcinoma. 
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